Emerging Immunotherapy Combinations and Novel Approaches for Oncology and Hematology: Keys to Designing and Operationalizing Your Trial

2

October

  • 4pm London, 11am New York, 8am San Francisco
  • Free

Why attend?

Understand how emerging immunotherapy combinations and novel approaches are influencing global clinical research in oncology and hematology, with a focus on clinical trial design innovations and mechanistic synergies.

The oncology and hematology clinical research landscape continues to be reshaped by emerging immunotherapy combinations and novel trial approaches. Researchers are exploring immunotherapy combinations to overcome treatment resistance, and ongoing clinical trials are evaluating their effectiveness when paired with other treatments.

It is critical to understand the science and technology behind these novel approaches, and to know how to operationalize them in a clinical trial setting.

 

Key Discussion Points:

  • Understanding advances in immune checkpoint inhibitors (ICIs), T-cell transfer therapy, monoclonal antibodies, antibody drug conjugates (ADC), immune system modulators, and cancer treatment vaccines
  • Trials to evaluate immunotherapy effectiveness when paired with targeted therapies, chemotherapy, or radiation in various cancers
  • Keys to developing an effective regulatory strategy for novel and immunotherapy studies
  • Navigate critical inflection points in your drug development process
  • Take advantage of medical, scientific, and operational collaboration

Speakers

Select a speaker to learn more

Back
Adam Callahan, MS, MBA
VP Global Therapeutic Area Head, Oncology & Hematology, Caidya

Adam Callahan is VP Global Therapeutic Area Head, Oncology & Hematology at Caidya. Adam brings nearly 30 years of experience and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of therapies. Adam leads a team of medical, scientific, and clinical development experts who engage early and often to help refine sponsor strategies, improve targeting, and accelerate delivery.

Adam’s teams also bring an adeptness in molecule-to-market strategies and operational excellence. Adam’s operational acumen ensures Caidya’s ability to provide development strategies while delivering exceptional experiences for our clients.

Next speaker
Back
Gonzalo Rubio, MD
Vice President, Medical Affairs. Oncology Medical Team Head

With over 30 years of clinical research experience, Gonzalo brings medical, scientific, and business insights to oncology drug development. His understanding of the clinical development – ranging from feasibility assessments, medical monitoring oversight, regulatory strategy, and patient safety enables him to provide valuable guidance to our biopharma partners.

Gonzalo is a board-certified Medical Oncologist with 15+ years of practice in the clinic and as an investigator before leading Global Oncology Medical Teams at the most renowned CROs.

Next speaker

Enquiry